The Role of PI3k/Akt/mTOR Signaling Pathway in Mediating Poly(ADP-Ribose) Polymerase Inhibitor (PARP1) Resistance in BRCA-Deficient Ovarian Cancer Patients
Scott Mayo Introduction. Platinu-based chemotherapy resistance has been a major challenge in BRCA deficient ovarian cancer patients.4,5,6,7,8 BRCA deficient cancer cells have a decreased ability to repair double stranded DNA breaks. This single hit mutation is advantageous to the cancer cells, allowing for mutation to be sustained.5 Studies have shown…